Newsroom

New report: Medication adherence plays critical role in heart disease disparities among blacks

National Forum

September 12, 2017

Posted in: News Releases

Authors find non-adherence to be a ‘driving force’ behind racial/ethnic disparities in cardiovascular disease, suggest strategies to address problem

 

Value & Access Steering Committee Comments on ICER New Evidence Update

National Forum

August 11, 2017

Posted in: News Releases

A summary of feedback from members of the Steering Committee and other partners engaged in the value & access space whose reflections represent the spectrum of stakeholder groups.

Medication adherence rates in U.S. unaffected by interventions

National Forum

January 23, 2017

Posted in: News Releases

People not taking prescribed medications is a major reason that heart disease and stroke persist as the leading cause of death, according to a new Journal of the American College of Cardiology report. The authors found that no single intervention has substantially altered medication adherence rates in the United States, and called for collaborative research to improve medication adherence among cardiovascular disease patients.

Government recommends new sodium levels for foods

National Forum

June 1, 2016

Posted in: News Releases

FDA and HHS issue new voluntarily guidelines to reduce sodium in processed and commercially prepared food. 

National Forum applauds Senate approval of new F.D.A. commissioner

National Forum

February 24, 2016

Posted in: News Releases

The National Forum for Heart Disease & Stroke Prevention congratulates Dr. Robert Califf on his confirmation as F.D.A. Commissioner.

National Forum orchestrates largest scale U.S. World Heart Day effort

National Forum

September 29, 2015

Posted in: News Releases

As part of the largest scale World Heart Day initiative in the organization's history, the National Forum for Heart Disease & Stroke Prevention is helping Americans take steps to reduce high cholesterol and other heart disease and stroke risk factors.

Statement on FDA Approval on Repatha™ (evolocumab)

National Forum

August 27, 2015

Posted in: News Releases

The National Forum is pleased that the U.S. Food and Drug Administration (FDA) approved Repatha™ (evolocumab), the second PCSK9 inhibitor to enter the market this year. 

National Forum's Statement on Praluent® FDA Approval

National Forum

July 24, 2015

Posted in: News Releases

Praluent® (alirocumab) Injection today to help reduce low density lipoprotein (LDL-C) or “bad” cholesterol in certain people whose high LDL-C levels put them at risk of heart attack or stroke.

National Forum's Statement on Entresto FDA Approval

National Forum

July 8, 2015

Posted in: News Releases

As an organization dedicated to improving cardiovascular health, the National Forum is excited that the FDA approved Entresto ™ (sacubitril/valsartan) as it has the potential to reduce heart failure mortality in the U.S.

Statement to the FDA's June 10, 2015 Endocrinologic and Metabolic Drugs Advisory Committee

John Clymer

June 10, 2015

Posted in: News Releases

The National Forum is encouraged by the efficacy data from recent PCSK9 inhibitor trials.

Pages